Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies
ConclusionsThe results from these long-term placebo-controlled studies confirm the established safety profile of long-acting OCT, in particular low risk of cardiac, hepatic and renal toxicity in a high-risk population.
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Acromegaly | Arrhythmia | Brain | Common Cold | Diabetes | Endocrinology | Gallstones | Hypertension | Liver | Neurology | Study | Toxicology | Urology & Nephrology